Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Vaccin Immunother
Autors principals: Stella, Maria, Giuliani, Maria, Biolchi, Alessia, Tomei, Sara, De Paola, Rosita, Bai, Xilian, Borrow, Ray, Lucidarme, Jay, La Gaetana, Rita, Toneatto, Daniela, Pizza, Mariagrazia, Serino, Laura, Mori, Elena, Giuliani, Marzia Monica
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227617/
https://ncbi.nlm.nih.gov/pubmed/31770063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1688039
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars